- Home
- UL vs GILD Comparison
UL vs GILD Comparison
Compare UL & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UL
- GILD
- Stock Information
- Founded
- UL 1930
- GILD 1987
- Country
- UL United Kingdom
- GILD United States
- Employees
- UL N/A
- GILD N/A
- Industry
- UL Package Goods/Cosmetics
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UL Consumer Discretionary
- GILD Health Care
- Exchange
- UL Nasdaq
- GILD Nasdaq
- Market Cap
- UL 153.7B
- GILD 129.9B
- IPO Year
- UL N/A
- GILD 1992
- Fundamental
- Price
- UL $61.27
- GILD $108.50
- Analyst Decision
- UL Buy
- GILD Buy
- Analyst Count
- UL 2
- GILD 25
- Target Price
- UL $72.00
- GILD $110.17
- AVG Volume (30 Days)
- UL 2.0M
- GILD 8.6M
- Earning Date
- UL 07-24-2025
- GILD 08-07-2025
- Dividend Yield
- UL 3.17%
- GILD 2.91%
- EPS Growth
- UL N/A
- GILD 1118.07
- EPS
- UL 2.37
- GILD 4.73
- Revenue
- UL $62,906,097,959.00
- GILD $28,735,000,000.00
- Revenue This Year
- UL $0.08
- GILD $1.55
- Revenue Next Year
- UL $3.58
- GILD $3.69
- P/E Ratio
- UL $25.75
- GILD $22.94
- Revenue Growth
- UL 1.94
- GILD 4.68
- 52 Week Low
- UL $54.32
- GILD $64.86
- 52 Week High
- UL $65.87
- GILD $119.96
- Technical
- Relative Strength Index (RSI)
- UL 38.12
- GILD 50.28
- Support Level
- UL $62.58
- GILD $107.19
- Resistance Level
- UL $63.55
- GILD $111.78
- Average True Range (ATR)
- UL 0.52
- GILD 2.85
- MACD
- UL -0.23
- GILD -0.43
- Stochastic Oscillator
- UL 4.42
- GILD 35.89
About UL Unilever PLC
Unilever is a diversified beauty, wellbeing, and personal care (44% of 2024 sales by value), homecare (20%), and packaged food (36%) company. Its brands include Dove personal-care products, Knorr soups and sauces, Hellmann's mayonnaise, Axe and Rexona deodorants, and TRESemmé haircare. The firm has been acquisitive in recent years; notable purchases include Paula's Choice, Liquid I.V., Horlicks, and Wild deodorants. The company derives 58% of its sales from emerging markets and 42% from developed markets. The US is its largest market, accounting for around 20% of sales, followed by India, which accounts for 11% of sales.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).